Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 20/20 | 0.48 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16899238 | 0.94 | IRAK4 (0.54) | IRAK4 | |
| SCHEMBL16899138 | 0.92 | IRAK4 (0.49) | IRAK4 | |
| SCHEMBL16898990 | 0.91 | IRAK4 (0.49) | IRAK4IRAK1 | |
| SCHEMBL16899228 | 0.90 | IRAK4 (0.57) | IRAK4IRAK1 | |
| SCHEMBL16898931 | 0.89 | IRAK4 (0.49) | IRAK4 | |
| SCHEMBL17383349 | 0.88 | IRAK4 (0.57) | IRAK4IRAK1 | |
| SCHEMBL16898875 | 0.87 | IRAK4 (0.58) | IRAK4IRAK1 | |
| SCHEMBL16898923 | 0.87 | IRAK4 (0.58) | IRAK4IRAK1 | |
| Hydrochloric Acid SCHEMBL17373933 | 0.87 | IRAK4 (0.57) | IRAK4IRAK1 | |
| SCHEMBL16899049 | 0.86 | IRAK4 (0.55) | IRAK4IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3092226-B1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2019-03-13 | — | — | EP | disclosed |
| US-10160753-B2 | Indazole compounds as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-12-25 | — | — | US | disclosed |
| EP-3092226-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-11-10 | — | — | US | disclosed |
| WO-2015104662-A1 | INDAZOLE COMPOUNDS AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160753-B2 | Indazole compounds as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885IRAK1 3/4885 |
| US-20160326151-A1 | Indazole Compounds as IRAK4 Inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885IRAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.